Summit Therapeutics Inc. (SMMT) · Sep 14, 2026 · Other events

Summit Therapeutics’ ivonescimab extends survival in HARMONi-2, but global proof remains pending

Above the bar — Median OS 30.8 vs 22.6 months; HR 0.73, p=0.009

Ivonescimab cut death risk versus pembrolizumab in HARMONi-2, strengthening Summit’s platform while leaving global validation and U.S. approval unresolved.

Summit is a clinical-stage oncology company trying to turn ivonescimab, a PD-1/VEGF bispecific, into a global lung-cancer platform. HARMONi-7 remains a recruiting global Phase III study, while the company’s first U.S. regulatory test is the HARMONi-based BLA, with an FDA action date of November 14, 2026.

The China trial cleared a meaningful efficacy bar. In 398 patients followed for 36 months, ivonescimab extended median overall survival to 30.8 months from 22.6 months with pembrolizumab, an 8.2-month gain and a 27% reduction in the risk of death. The interim OS result was statistically significant at HR 0.73 with p=0.009 (HARMONi-2 ITT). 〔0〕

MeasureIvonescimabPembrolizumabComparison
Median overall survival30.8 months22.6 months+8.2 months
Overall-survival hazard ratio——0.73; 95% CI 0.57–0.95; p=0.009
PD-L1-high subgroup HR——0.58; 95% CI 0.38–0.89
Serious treatment-related adverse events29.9%21.6%Higher with ivonescimab
Treatment-related discontinuations4.1%5.0%Slightly lower with ivonescimab

The result matters most because it strengthens the exact setting Summit is pursuing globally. HARMONi-2 tested monotherapy against pembrolizumab in PD-L1-positive NSCLC, while HARMONi-7 is testing the same basic comparison in a global population with PD-L1 expression above 50%. The especially strong PD-L1-high subgroup HR of 0.58 gives HARMONi-7 a more supportive precedent, although the subgroup analysis was descriptive and not formally powered (HARMONi-2 subgroup analyses).

The readout is validation, not a new commercial approval. Akeso already received Chinese authorization based on HARMONi-2, and Summit had already disclosed the positive OS direction before this filing; the new value is the mature survival detail and subgroup depth. Ivonescimab remains investigational in Summit’s license territories, including the United States and Europe, so this does not by itself establish regulatory success there. 〔1〕

The safety profile is manageable but not cleaner across every measure. The filing says there were no new safety signals with longer follow-up, and discontinuations were not higher, but serious treatment-related adverse events occurred more often with ivonescimab than with pembrolizumab. 〔2〕

Bottom line: This is a genuinely strong efficacy confirmation for ivonescimab and raises the evidentiary support for HARMONi-7. It is still China-only partner data, so the central business question—whether the benefit translates into global populations and Summit’s U.S. market—remains open.

What to watch next

HARMONi-7 global readout; HARMONi BLA decision, November 14

Original filing on SEC EDGAR

More Summit Therapeutics Inc. news

Summit Therapeutics’ ivonescimab extends survival in HARMONi-2, but global proof remains pending | SMMT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.